Emergent BioSolutions Inc. (NYSE:EBS) announced that it has submitted a Biologics License Application to the U.S. Food and Drug Administration (FDA) for Anthrax Immune Globulin Intravenous (Human) [AIGIV] as part of a development contract with the Biomedical Advanced Research and Development Authority (BARDA). AIGIV, which was acquired in the Cangene acquisition completed earlier this year, is being developed as an intravenous therapeutic treatment for inhalation anthrax. Emergent BioSolutions, Inc. (NYSE:EBS) belongs to Healthcare sector. Its net profit margin is 3.80% and weekly performance is 3.50%. On last trading day company shares ended up $23.35. Emergent BioSolutions, Inc. (NYSE:EBS) distance from 50-day simple moving average (SMA50) is 3.38%.
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the second quarter ended June 30, 2014, after the market close on Wednesday, August 13, 2014. Conatus will host a conference call and audio webcast at 4:30 p.m. Eastern Time on Wednesday, August 13, 2014, to discuss the financial results and provide a corporate update. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) shares advanced 3.86% in last trading session and ended the day at $7.54. CNAT return on assets is -22.50%. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) quarterly performance is 37.84%.
Cabot Microelectronics (NASDAQ:CCMP) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a research report issued on Tuesday. On 11 August, Cabot Microelectronics Corporation (NASDAQ:CCMP) shares advanced 1.68% and was closed at $42.35. CCMP EPS growth in last 5 year was 5.50%. Cabot Microelectronics Corporation (NASDAQ:CCMP) year to date (YTD) performance is -7.33%.
MakeMyTrip Limited (NASDAQ:MMYT) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a note issued to investors on Wednesday. MakeMyTrip Limited (NASDAQ:MMYT) ended the last trading day at $29.70. Company weekly volatility is calculated as 4.11%and price to cash ratio as 18.31. MakeMyTrip Limited (NASDAQ:MMYT) showed a weekly performance of -1.00%.
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath® technology, today announced financial results for the first quarter of fiscal 2015, ended June 30, 2014. Vision-Sciences Inc. (NASDAQ:VSCI) shares moved down -4.17% in last trading session and ended the day on $0.92. VSCI Gross Margin is 26.30% and its return on assets is -69.80%. Vision-Sciences Inc. (NASDAQ:VSCI) quarterly performance is -12.38%.